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Abstract
Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common genetic cause of Parkinson’s
disease. Here, we investigated whether the G2019S LRRK2 mutation causes morphological and/or functional
changes at nigro-striatal dopamine neurons. Density of striatal dopaminergic terminals, nigral cell counts, tyrosine
hydroxylase protein levels as well as exocytotic dopamine release measured in striatal synaptosomes, or striatal
extracellular dopamine levels monitored by in vivo microdialysis were similar between ≥12-month-old G2019S
knock-in mice and wild-type controls. In vivo striatal dopamine release was insensitive to the LRRK2 inhibitor
Nov-LRRK2-11, and was elevated by the membrane dopamine transporter blocker GBR-12783. However, G2019S
knock-in mice showed a blunted neurochemical and motor activation response to GBR-12783 compared to wild-
type controls. Western blot and dopamine uptake analysis revealed an increase in dopamine transporter levels and
activity in the striatum of 12-month-old G2019S KI mice. This phenotype correlated with a reduction in vesicular
monoamine transporter 2 levels and an enhancement of vesicular dopamine uptake, which was consistent with
greater resistance to reserpine-induced hypolocomotion. These changes were not observed in 3-month-old mice.
Finally, Western blot analysis revealed no genotype difference in striatal levels of endogenous α-synuclein or
α-synuclein bound to DOPAL (a toxic metabolite of dopamine). However, Serine129-phosphorylated α-synuclein
levels were higher in 12-month-old G2019S knock-in mice. Immunohistochemistry confirmed this finding, also
showing no genotype difference in 3-month-old mice. We conclude that the G2019S mutation causes progressive
dysfunctions of dopamine transporters, along with Serine129-phosphorylated α-synuclein overload, at striatal
dopaminergic terminals, which are not associated with dopamine homeostasis dysregulation or neuron loss but
might contribute to intrinsic dopaminergic terminal vulnerability. We propose G2019S knock-in mice as a
presymptomatic Parkinson’s disease model, useful to investigate the pathogenic interaction among genetics, aging,
and internal or environmental factors leading to the disease.
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Introduction
Autosomal-dominant missense mutations in the leucine-
rich repeat kinase 2 (LRRK2) gene (PARK8, OMIM
609007) cause familial late-onset Parkinson’s disease (PD)
[59, 95]. LRRK2 mutations also occur in 1–2% of sporadic
cases [28, 70] and recent genome wide association studies
(GWAS) showed that common variations in the LRRK2
locus increase the risk of disease, pointing to a crucial role
of LRRK2 in the pathogenesis of PD. LRRK2-associated
PD is clinically and pathologically indistinguishable from
the idiopathic form [18], although some differences in
motor and non-motor features have been reported [46].
The majority of LRRK2 autoptic cases report progressive
degeneration of dopamine (DA) neurons located in the
substantia nigra pars compacta (SNpc), and α-synuclein
(α-syn)/ubiquitin-positive intraneuronal cytoplasmic
inclusions in surviving neurons [31, 33], although a
pleomorphic pathology associated with other neurode-
generative diseases has also been observed [95]. Despite
the undisputed genetic link between LRRK2 mutations
and PD, the pathogenic mechanisms through which
LRRK2 mutations affect PD onset and progression
remain debated [17, 49]. LRRK2 is a complex multi-
domain protein belonging to the ROCO family, character-
ized by the presence of a GTPase and a serine-threonine
kinase domain surrounded by a number of protein-
protein interaction domains [16, 51]. The most common
LRRK2 pathogenic mutations are represented by Gly2019-
Ser (G2019S) in the kinase domain, followed by the hot-
spot mutation Arg1441Cys/Gly/His/Ser (R1441C/G/H/S)
in the GTPase domain [19, 73]. The G2019S mutation re-
sults in a two to threefold increase in LRRK2 kinase activ-
ity, which appears to be crucial for LRRK2-induced
neurodegeneration in vitro [26, 90, 91]. More recently,
the cellular activity of LRRK2, probed with anti-
autophosphorylation antibodies against Serine 1292
[67, 72] and by measuring the phosphorylation of a
subset of Rab GTPase which are bona fide LRRK2 cel-
lular substrates [76], revealed a homogeneous increase
of LRRK2 kinase activity in the presence of pathogenic
mutations, which is not limited to the G2019S mutant
as it occurs in vitro.
Various LRRK2 rodent models have been generated in
the attempt to replicate the dysfunction and/or degener-
ation of the nigro-striatal dopaminergic pathway in vivo.
Unfortunately, these models provided conflicting data.
Mice overexpressing human G2019S or R1441C/G
mutations through BAC technology did not show overt
dopaminergic neurodegeneration [39, 40, 53] but re-
duced striatal DA content or basal extracellular levels in
vivo when compared to non-transgenic wild-type con-
trols [4, 53]. Consistently, the K+-evoked DA release was
reduced in striatal slices from BAC hG2019S mice [40].
In mice where hG29019S [13, 64] or hR1441C [88]
overexpression in SNc was achieved through the CMV/
PDGF promoter, an 18–50% reduction in the number of
nigral DA cells was observed at old ages (16–21
months). In these mice, no changes of in vivo DA con-
tent was observed [64], although the K+-evoked DA re-
lease from striatal slices was reduced [88]. Conditional
expression of hG2019S [41] or hR1441C [83] in SNc also
did not cause nigral DA neuron loss; only a mild reduction
in the density of TH terminals was observed in 16-month-
old mice [41]. In these mice, hG2019S overexpression
caused a reduction of DA content and release from striatal
slices [41]. Lack of nigro-striatal degeneration [37, 74, 93]
or changes in DA content [37, 93] were also confirmed in
transgenic rats overexpressing hG2019S or hR1441C mu-
tations. In vitro, a reduction of the K+-evoked DA release
in BAC overexpressing rats was found [74]. Finally, no
overt neurodegeneration [29, 82, 92] or changes in striatal
DA content [29, 82] were observed in G2019S or R1441C
knock-in (KI) mice, although in vivo microdialysis
revealed a 60% reduction in both spontaneous and
amphetamine-induced DA release in 12-month-old
G2019S KI mice [92].
In a previous longitudinal study, we reported that
G2019S KI mice had enhanced motor behavior com-
pared to both WT mice and mice carrying the D1994S
kinase-dead mutation [43]. In this follow-up study, we
sought to investigate the mechanisms underlying such
phenotype, and in particular, whether G2019S LRRK2 is
associated with dysregulation of nigro-striatal DA trans-
mission. Indeed, in vivo [93] and in vitro [54] evidence
that the G2019S mutation can be associated with in-
creased DA release has been presented. Here, different
aspects of striatal DA transmission were evaluated,
namely the integrity of the nigro-striatal DA pathway, in
vivo and in vitro striatal DA release, expression and
function of proteins involved in synaptic load (DA trans-
porter, DAT) or vesicle storage (vesicular monoamine
transporter type 2; VMAT2) of DA, and, finally, the
levels of endogenous α-syn, and its Serine129 phosphor-
ylated (pSer129 α-syn) or 3,4-dihydroxyphenylacetalde-
hyde (DOPAL)-bound forms, which are considered
markers of synaptic damage.
Materials and methods
Animals
Male homozygous LRRK2 G2019S KI mice, backcrossed
on a C57Bl/6 J background, were used. Mice were ob-
tained from Novartis Institutes for BioMedical Research,
Novartis Pharma AG (Basel, Switzerland) [29], and bred
in the vivarium of the University of Ferrara. In behav-
ioral and neurochemical studies, male non-transgenic
wild-type (WT) mice were littermates obtained from the
heterozygous breeding. Otherwise, WT mice were ob-
tained from homozygous breeding. Mice were kept
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under regular lighting conditions (12 h light/dark cycle)
and given food and water ad libitum. Experimental pro-
cedures involving the use of animals were approved by
the Ethical Committee of the University of Ferrara and
the Italian Ministry of Health (licenses 171/2010-B and
318/2013-B). Adequate measures were taken to minimize
animal pain and discomfort.
Behavioral pharmacology
Three behavioral tests specific for different motor abil-
ities, i.e. the bar, drag and rotarod tests, were used as de-
scribed [43, 84, 85]. Experimenters were unaware of
genotype and treatments. Twelve-month-old mice were
acutely administered i.p. with the VMAT2 inhibitor re-
serpine at the doses of 1 or 2 mg/kg [87], or with the
DAT inhibitor GBR-12783 at the dose of 6 mg/kg.
The bar test measures the ability of the animal to re-
spond to an externally imposed static posture. Mice
were gently placed on a table and forepaws were placed
alternatively on blocks of increasing heights (1.5, 3 and
6 cm). The time (in seconds) that each paw spent on the
block (i.e. the immobility time) was recorded (cut-off
time of 20 s). Performance was expressed as total time
spent on the different blocks. The drag test measures
the ability of the animal to balance its body posture with
the forelimbs in response to an externally imposed dy-
namic stimulus (backward dragging) [47]. It gives infor-
mation regarding the time to initiate and execute
(bradykinesia) a movement. Animals were gently lifted
from the tail leaving the forepaws on the table, and then
dragged backwards at a constant speed (about 20 cm/s)
for a fixed distance (100 cm). The number of steps made
by each paw was recorded. Five to seven determinations
were collected for each animal. Finally, the fixed-speed
rotarod test integrates different motor parameters such
as motor coordination, gait ability, balance, muscle tone
and motivation to run. Mice were tested over a wide
range of increasing speeds (0–55 rpm; 5 rpm steps, in-
creased every 180 s) on a rotating rod (diameter of the
cylinder 8 cm) and the total time spent on the rod was
recorded [84, 85]
In vivo microdialysis
Two concentric microdialysis probes (1 mm Cuprophane
membrane with a 6 kDa cut-off; AgnTho’s, Stockolm,
Sweden) were stereotaxically implanted under isoflurane
anesthesia in both dorsal striata (coordinates from the
bregma: AP +0.6, ML ±2.0, DV −2.0) [62]. Twenty-four
hours after implantation, probes were perfused (2.1 μl/
min) with a modified Ringer solution (in nM CaCl2 1.2;
KCl 2.7; NaCl 148 and MgCl2 0.85) and samples were col-
lected every 20 min [6, 45, 87] after a 6 h wash-out
period. Experiments were run at 24 and 48 h after im-
plantation, and treatments were randomized. GBR-
12783 and Nov-LRRK2-11 were administered at 20 mg/
kg (i.p.) and 10 mg/kg (i.p.), respectively.
Neurochemical analysis using LC-MS
DA, HVA, DOPAC and 3MT concentrations in dialy-
sates were analyzed using a benzyolation derivatization
LC-MS method described by [75]. Briefly, 5 μl dialysate
samples were derivatized by adding 2.5 μl of 100 mM
sodium tetraborate, 2.5 μl of 2% benzoyl chloride in
acetonitrile, and 2.5 μl of a stable 13C benzoylated iso-
tope internal standard mixture for improved quantita-
tion. A Thermo Fisher Accela UHPLC (Waltham, MA)
system automatically injected 5 μl of the sample onto a
Waters (Milford, MA) HSS T3 reverse phase HPLC col-
umn (1 mm X 100 mm, 1.8 μm). Mobile phase A con-
sisted of 10 mM ammonium formate and 0.15% formic
acid. Mobile phase B was pure acetonitrile. Analytes
were detected by a Thermo Fisher TSQ Quantum Ultra
triple quadrupole mass spectrometer operating in mul-
tiple reaction monitoring (MRM) mode. Run times were
approximately 6 min and all analytes could be detected
well above quantification limits (data not shown).
Synaptosomes preparation
Mice were anesthetized and decapitated. Striata from
each mouse were homogenized in ice-cold 0.32 M su-
crose (pH 7.4) with a Teflon-glass homogenizer and cen-
trifuged at 9,500 g for 10 min at 4 °C. The supernatant
was then centrifuged at 10,000 g for 20 min at 4 °C, and
the pellet processed for (i) release experiments or (ii)
DA uptake assay.
Release experiments
The pellet was resuspended in 1.5 ml of pre-oxygenated
Krebs solution (in mM: NaCl 118.5, KCl 4.7, CaCl2 1.2,
MgSO4 1.2, KH2PO4 1.2, NaHCO3 25, glucose 10, ascor-
bic acid 0.05, disodium EDTA 0.03, pH 7.4) and incu-
bated with 50 nM [3H]-DA (specific activity 40 Ci/
mmol; Perkin-Elmer, Boston, MA, USA) for 25 min at
36.5 °C [48]. At the end of the incubation, 12 ml of pre-
oxygenated Krebs were added, then 1 ml aliquots of the
suspension (~0.35 mg protein) were injected into nylon
syringe filters maintained at 36.5 °C and superfused
(0.4 ml/min) with pre-oxygenated Krebs. Under these
superfusion conditions, spontaneous [3H]-DA efflux is
essentially unaffected by reuptake [48]. Sample collec-
tion (every 3 min) was initiated after a 20 min period of
filter washout. Radioactivity in the samples and in the
filters was measured using a Perkin Elmer Tri Carb 2810
TR scintillation counter.
DA uptake assay
The pellet was resuspended in ice-cold uptake buffer (in
mM: NaCl 125, KCl 5, MgSO4 1.5, CaCl2 1.2, KH2PO4
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1.5, glucose 10, HEPES 25, pargyline 0.1, ascorbic acid
0.5, pH 7.4) and incubated for 5 min at 37 °C with 20
nM [3H]-DA isotopically diluted with varying concentra-
tions of unlabeled DA to obtain final DA concentrations
in the 20–2000 nM range. Non-specific DA uptake was
evaluated in the presence of 5 μM GBR-12783. The reac-
tion was terminated by filtering the assay mixture through
Whatman GF/B glass fiber filters using a Brandel cell
harvester (Brandel Instruments, Unterföhring, Germany).
The filter-bound radioactivity was counted using a Perkin
Elmer Tri Carb 2810 TR scintillation counter. Specific DA
uptake, defined as the difference between DA accumu-
lated in the absence and in the presence of GBR-12783,
was expressed as pmol/mg protein/min [94]. Protein con-
centration was determined using a Bio-Rad method with
bovine albumin as standard reference. Kinetic parameters
(Vmax and Km) were determined using Prism 5.0 (Graph-
Pad Software Inc., San Diego, CA).
Western blot analysis
Mice were anesthetized and decapitated. Striata were
solubilized and homogenized in lysis buffer (RIPA buffer,
protease and phosphatase inhibitor cocktail) and centri-
fuged at 13,000 rpm for 15 min at 4 °C. Supernatants
were collected and total protein levels were quantified
using the bicinchoninic acid protein assay kit (Thermo
Scientific). Thirty micrograms of protein per sample
were separated by SDS-PAGE, transferred onto polyvi-
nyldifluoride membrane and tested for the following pri-
mary antibodies: rabbit anti-tyrosine hydroxylase (TH)
(Merck Millipore, AB152, 1:1000), rabbit anti-DAT
(Sigma Aldrich, D6944, 1:1000), rabbit anti-VMAT2
(Sigma Aldrich, V9014, 1:300), rabbit anti-VMAT2
(Miller Lab, Emory University, 1:1000 [15]), rabbit anti-
pSer129 α-syn (Abcam, ab51253, 1:1000), rabbit anti
pSer1292 LRRK2 (Abcam, ab203181, 1:300). Appropriate
horseradish peroxidase-linked secondary antibodies
(Merck Millipore, goat anti-rabbit IgG HRP-conjugate
12–348, 1:4000 or goat anti-rat IgG HRP-conjugate
AP136P, 1:5000) were then used and immunoreactive
proteins were visualized by enhanced chemilumines-
cence (ECL) detection kit (Pierce™ BCA Protein Assay
Kit, Thermo Scientific or ECL+, GE Healthcare). Images
were acquired and quantified using the ChemiDoc MP
System and the ImageLab Software (Bio-Rad). Mem-
branes were then stripped and re-probed with rabbit
anti-GAPDH antibody (Thermo Scientific, PA1-988,
1:1000), rabbit anti-LRRK2 (Abcam, ab133474, 1:300) or
rabbit anti-α-syn antibody (Abcam, ab52168, 1:1000).
Data were analyzed by densitometry and the optical
density of specific target protein bands was normalized
to the corresponding housekeeper protein levels.
DOPAL-bound α-syn was revealed using ABPA resin
(Sigma Aldrich, A8530) pulldown [35, 66]. Five-hundred
micrograms total protein were incubated with 50 μl of
the resin overnight at 4 °C shaking. The resin was then
pelleted, the supernatant removed and the resin was
washed twice with PBS/acetonitrile and water. Protein
was collected from the resin by adding 20 μl Laemmli
buffer and processed as described above using the anti-
α-syn antibody. The band intensity was quantified by
Image J software and the pull down protein was com-
pared with the total lysate.
Immunohistochemistry
Mice were deeply anesthetized with isoflurane and trans-
cardially perfused with 4% paraformaldehyde in Phos-
phate Buffer Solution (PBS; 0.1 M, pH 7.4). Brains were
removed, transferred to a 30% sucrose solution in PBS
for cryoprotection and then stored at −80 °C.
TH, α-syn and pSer129 α-syn immunohistochemistry
Fifty micrometer free-floating sections of striatum (AP
from +1.42 to +0.14 from bregma) and SNc (AP from
−3.16 to −3.52 from bregma [62]) were rinsed in PBS
incubated for 30 min at room temperature with a
blocking solution (PBS + BSA 1:50 + Triton X100 0.3%)
and then incubated with a rabbit polyclonal antibody
raised against TH (ab112; 1:750 in BSA 1% PBST;
Abcam, Cambridge, UK), α-syn (ab52168; 1:250 in BSA
1% PBST; Abcam, Cambridge, UK) or pSer129 α-syn
(ab52153; 1:200 in BSA 1% PBST; Abcam, Cambridge,
UK) overnight at 4 °C. Sections were then rinsed and
incubated with an anti-rabbit HRP-conjugated second-
ary antibody (ab6721, 1:500 in BSA 1% PBST; Abcam,
Cambridge UK) and revealed by a DAB substrate kit
(ab64238, Abcam, Cambridge, UK). Sections were
mounted on gelatinized slides, dehydrated and cover-
slipped for further analysis. To quantify the levels of
expression of α-syn and pSer129 α-syn, the semi-
stereological method described by Bourdenx et al. [7]
was employed. This method has been rigorously stan-
dardized; in fact all serial striatal slices for each animal
were taken, marked, put in the same well and exposed
to DAB for 1 min (according to the data sheet of
Abcam DAB substrate Kit). After being mounted, slides
were scanned and the representative surface of the
staining in each SN section was determined using a
color threshold, then the area was sampled (probes of
50 × 40 μm, space 150 × 120 μm). The Cavalieri
principle was applied to evaluate the representative
volume of α-syn or pSer129 α-syn expression for each
SN. The SN volume obtained from the α-syn staining
was used to calculate the pSer129 α-syn expression as
a percentage, thus allowing the comparison between
the two different groups.
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Stereology and neuron counting
Stereological analysis was performed counting TH+
neurons (phenotypic marker) and cresyl violet stained
cells (structural marker) in SNc, according to an un-
biased stereological sampling method based on optical
fractionator stereological probe [34]. A Leica DM6000B
motorized microscope coupled with the Mercator Pro
software (Mercator Digital Imaging System, Explora
Nova, La Rochelle, France) was used [2, 5, 7]. Counting
was performed on at least 5 consecutive 50 μm thick
slices, magnified at 40X.
VMAT2 activity assay
Mice were anesthetized and decapitated. Whole brains
were homogenized in ice-cold buffer (4 mM HEPES,
0.32 M sucrose, pH 7.4) and centrifuged at 1,000 g for
10 min at 4 °C [10]. Supernatants were centrifuged at
20,000 g for 20 min at 4 °C, the resulting pellets were
resuspended in 1.6 ml of resuspension buffer (0.32 M
sucrose, pH 7.4) and subjected to osmotic shock by 10
up-and-down strokes in 6.4 ml of ice-cold water
followed by addition of 1 ml of 250 mM HEPES and
1 M potassium tartrate, pH 7.4, to restore osmolarity.
Samples were then centrifuged at 20,000 g for 20 min at
4 °C, and supernatants were centrifuged at 120,000 g for
2 h at 4 °C. Final pellets containing synaptic vesicles
were resuspended in assay buffer (100 mM potassium
tartrate, 25 mM HEPES, 0.1 mM EDTA, 0.05 mM
EGTA, 1.7 mM ascorbate, 2 mM ATP disodium salt,
pH 7.4) and incubated for 5 min at 37 °C with 20 nM
[3H]-DA isotopically diluted with varying concentrations
of unlabeled DA. Non-specific DA uptake was evaluated
in the presence of 10 μM tetrabenazine. The reaction
was terminated by filtering the assay mixture through
0.5% polyethylenamine-soaked Whatman GF/B glass
fiber filters using a Brandel cell harvester. The filter-
bound radioactivity was counted using a Perkin Elmer
Tri Carb 2810 TR scintillation counter.
Data presentation and statistical analysis
Data are expressed as percentage of baseline (behav-
ioral experiments) or absolute values and are mean
± SEM (standard error of the mean) of n mice. Stat-
istical analysis of drug effect was performed by one-
way conventional or repeated measure (RM) analysis
of variance (ANOVA) followed by the Newman-
Keuls test for multiple comparisons, or by two-way
ANOVA followed by Bonferroni test for multiple
comparisons. The Student t-test, two tailed for un-
paired data, was used to compare two groups of
data. P-values <0.05 were considered to be statisti-
cally significant.
Drugs
GBR-12783 dihydrochloride and reserpine were purchased
from Tocris Bioscience (Bristol, UK). Nov-LRRK2-11 was
obtained from Novartis Institutes for BioMedical Re-
search, Novartis Pharma AG (Basel, Switzerland).
Results
The nigro-striatal DA pathway is intact in G2019S KI mice
To confirm that the G2019S KI mice under study pos-
sess enhanced LRRK2 kinase activity, we monitored
LRRK2 autophosphorylation levels at Ser1292 using
Western blotting. We found that pSer1292 levels were
~8-fold higher in the striatum of 12-month-old G2019S
KI mice compared to age-matched WT littermates
(Fig. 1), indicating a clear-cut gain of kinase activity in
the presence of the G2019S mutation.
We next investigated the possibility that the G2019S
mutation compromises the integrity of nigro-striatal DA
neurons (Fig. 2). No differences in nigral DA cell number
or density of striatal TH-positive terminals were detected
between 12-month-old (Fig. 2a and b, respectively) or 19-
month-old (data not shown) G2019S KI and WT mice.
Likewise, striatal TH levels were similar between geno-
types in 12-month-old animals (Fig. 2c).
Striatal DA release is preserved in G2019S KI mice
To investigate whether the exocytotic properties of DA
terminals were affected by the G2019S mutation (Fig. 3),
synaptosomes obtained from the striatum of 12-month-
old mice were depolarized with a sequence of three 90-s
pulses (18 min away) of 10 mM or 20 mM K+ (Fig. 3a).
No differences in spontaneous [3H]-DA efflux (Fig. 3a)
and K+-evoked [3H]-DA overflow (Fig. 3a,b) were
observed between G2019S KI mice and aged-matched
WT controls, both after a single or repeated pulses, sug-
gesting that enhanced LRRK2 kinase activity is not asso-
ciated with changes of striatal DA release. Consistently,
in vivo microdialysis revealed no significant differences
in dialysate levels of DA and DA metabolites (DOPAC,
HVA and 3-MT) between 19-month-old G2019S KI
mice and WT littermates (Table 1), although a trend for
higher DA and lower metabolites levels in G2019S KI
mice was observed. Indeed, significant reductions of
HVA/DA and 3-MT/DA ratios in G2019S KI mice were
found, the reduction of DOPAC/DA ratio being close
to significance (p = 0.067; Table 1), suggesting a slower
DA metabolism in G2019S KI mice Microdialysis also
revealed that the LRRK2 kinase inhibitor Nov-LRRK2-
11 (10 mg/kg, i.p.), which normalizes motor perform-
ance in G2019S KI mice [43], did not affect striatal DA
release in any genotypes (Fig. 4a), suggesting the motor
phenotype of G2019S KI mice did not rely on greater
DA release.
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Age-dependent dysfunction of DAT in G2019S KI mice
Since extracellular DA levels strongly rely on DAT activ-
ity, we investigated whether the trend for an increase in
extracellular DA levels observed in G2019S KI mice was
associated with changes in DAT activity. Microdialysis
showed that striatal DA levels were elevated in both
genotypes after administration of the DAT blocker GBR-
12783 (20 mg/Kg, i.p) (Fig. 4b). However, the response
in WT mice was more rapid and larger (maximum ∼ 3-
fold over basal) compared to that in G2019S KI mice
that was delayed and blunted (∼2-fold over basal)
(Fig. 4b).
To confirm dysfunctional DAT activity, we monitored
motor performances following GBR-12783 administra-
tion. As previously reported [43], G2019S KI mice were
more active (p < 0.001) in the bar and drag tests (18.29 ±
1.62 s and 13.67 ± 0.47 steps, respectively; n = 60) com-
pared to WT littermates (31.57 ± 1.65 s and 9.92 ± 0.39
Fig. 1 Phosphorylation levels of LRRK2 at Ser1292 (pSer1292) are elevated in G2019S knock-in (KI) mice. Striatal pSer1292 and total LRRK2 levels
were measured by Western blotting in 12-month-old G2019S KI mice and age-matched WT controls. Representative blots (left) and quantification
(right) are shown. Data are expressed as pSer1292 LRRK2/total LRRK2 and are means ± SEM of 7 animals per group. Statistical analysis was performed
with the Student t-test, two tailed for unpaired data. **p < 0.01, different from WT
Fig. 2 The integrity of nigro-striatal dopaminergic neurons is preserved in G2019S knock-in (KI) mice. Stereological count of nigral DA neurons
(a) and density of tyrosine hydroxylase (TH) positive striatal nerve terminals (b), with representative images, in 12-month-old G2019S KI mice and
age-matched WT littermates. Western blotting analysis of striatal TH levels in 12-month-old G2019S KI mice and age-matched WT controls (c).
Data are expressed as absolute values and are means ± SEM of 8 (a-b) and 4 (c) animals per group
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steps, respectively; n = 58). Conversely, rotarod perform-
ance was similar in G2019S KI and WT mice (837.58 ±
21.73 and 872.2. ± 31.89 s, respectively). GBR-12783
(6 mg/Kg) reduced the immobility time (Fig. 4c) and in-
creased the stepping activity (Fig. 4d) in WT but not
G2019S KI mice, while causing a delayed increase in
rotarod performance in both genotypes (Fig. 4e).
We then investigated DAT expression and function
in striatal synaptosomes from 12-month-old mice
(Fig. 5a, b). Analysis of DA uptake kinetics (Fig. 5a) re-
vealed a significant 63% increase of maximal transport
rate (Vmax) in striatal synaptosomes from G2019S KI
mice (33.1 ± 1.4 pmol/mg prot/min) with respect to
WT mice (20.2 ± 1.1 pmol/mg prot/min; p < 0.01),
without changes in the DA affinity for the transporter
(Km 76.3 ± 8.5 nM vs 67.9 ± 9.0 nM in G2019S KI and
WT mice, respectively). Consistent with higher Vmax,
Western blot analysis showed that DAT protein levels
were ~4-fold higher in G2019S KI than WT mice
(Fig. 5b). To investigate whether these changes were
age-dependent, experiments were replicated in youn-
ger animals (Fig. 5c,d). No differences were observed
in [3H]-DA uptake kinetics between 3-month-old
G2019S KI mice (Km 66.2 ± 10.1 nM, Vmax 26.5 ± 1.7
nM) and age-matched WT controls (Km 70.5 ± 10.6
nM, Vmax 25.3 ± 0.6 nM) (Fig. 5c). Likewise, protein
levels were similar between genotypes at this age
(Fig. 5d).
Age-dependent dysfunction of VMAT2 in G2019S KI mice
Since the DAT/VMAT2 ratio is a vulnerability factor in
DA neurons [56], we next investigated whether VMAT2
was also dysfunctional in G2019S KI mice (Fig. 6). First,
the VMAT2 blocker reserpine was administered (1 mg/
Kg, i.p.) to 12-month-old mice (Fig. 6a-c). G2019S KI
and WT mice showed similar increases of immobility
time 24 h after reserpine administration, although
G2019S KI mice were also affected at 48 h (Fig. 6a).
Conversely, reserpine reduced stepping activity (Fig. 6b)
and rotarod performance (Fig. 6c) selectively in WT
mice, both at 24 h and 48 h after administration. Higher
reserpine doses (2 mg/Kg), however, caused similar
motor impairments in both genotypes (data not shown).
We then measured VMAT2 uptake activity in a prepar-
ation of whole-brain synaptic vesicles (Fig. 6d). VMAT2
affinity for DA (Km) was similar between 12-month-old
G2019S KI mice and WT controls (356.3 ± 25.2 vs 333.6
± 31.0 nM, respectively), although Vmax was significantly
higher in G2019S KI mice (52.7 ± 2.4 vs 43.2 ± 2.2 nM,
respectively; p < 0.05). Striatal VMAT2 protein levels
were then analyzed, comparing a commercially available
(Fig. 6e) with an in-house validated [15] antibody
(Fig. 6f ). Both antibodies revealed a ~50% reduction of
VMAT2 levels in G2091S KI mice. Finally, VMAT2 ac-
tivity and protein levels were measured in 3-month-old
mice (Fig. 6g-i). As for DAT, no differences between ge-
notypes were observed at this age.
a
b
Fig. 3 Dopamine (DA) release is preserved in G2019S knock-in (KI)
mice. [3H]-DA preloaded synaptosomes obtained from the striata of
12-month-old G2019S KI mice and age-matched WT littermates were
continuously superfused with Krebs and stimulated with 3 pulses
(90 s) of 10 mM or 20 mM K+ (18 min apart). DA release has been
expressed as fractional release (FR; i.e. tritium efflux expressed as
percentage of the tritium content in the filter at the onset of the
corresponding collection period; a), or NET FR (i.e. K+-evoked tritium
overflow as percent of the tritium content in the filter at the onset
of the corresponding collection period; b). Data are means ± SEM of
9 determinations per group
Table 1 Basal dialysate levels (nM) of DA and its metabolites DOPAC, 3-MT and HVA monitored using in vivo microdialysis in the
dorsal striatum of 19-month-old G2019S knock-in mice (G2019S KI) and wild-type littermates (WT)
genotype DA DOPAC HVA 3-MT DOPAC/DA HVA/DA 3-MT/DA
WT nM 0.28 ± 0.06 47.31 ± 15.98 82.39 ± 21.44 0.99 ± 0.51 247.63 ± 112.25 242.30 ± 36.65 2.96 ± 0.87
G2019S KI nM 0.36 ± 0.06 22.12 ± 5.63 54.74 ± 11.63 0.42 ± 0.082 48.65 ± 10.39 114.00 ± 36.50* 1.14 ± 0.24*
*p < 0.05, significantly different from WT
The metabolite/DA ratios are also reported. Data are means ± SEM of 11–15 determinations per group and were analyzed using the Student t-test, two-tailed for
unpaired data
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Age-dependent increase of pSer129 α-syn in G2019S
KI mice
An increase of DAT activity [50] can lead to an increased
cytosolic DA levels and buildup of byproducts of DA
metabolism which are toxic for the cell. Among these,
DOPAL [8, 52, 60], which is known to covalently bind to
α-syn at lysine residues [21, 89]. We therefore measured
DOPAL-bound α-syn levels in the striatum of 12-
month-old G2019S KI mice compared to WT controls
(Fig. 7a). No significant difference between genotypes
was found. We then investigated pSer129 α-syn levels
(Fig. 7b, c), since this posttranslational modification of
α-syn is thought to influence α-syn aggregation and is
highly represented in intracellular inclusions and Lewy
Bodies [1, 24, 69]. Total endogenous α-syn levels were
not different between genotypes (Fig. 7b) whereas
pSer129 α-syn levels were ~2-fold higher in the striatum
of G2019S KI mice (Fig. 7c). To study the localization of
α-syn and pSer129 α-syn, immunohistochemistry was
employed in striatal slices from 12-month-old mice
(Fig. 8). α-syn and pSer129 α-syn inclusions were re-
vealed in striatal neurons of both genotypes, seemingly
at the cell body level. Endogenous α-syn levels did not
differ between genotypes (Fig. 8a), while pSer129 α-syn
inclusions were significantly higher in the striatum of
G2019S KI mice compared to WT controls (Fig. 8b). We
next confirmed that such increase was age-dependent,
since no difference in striatal α-syn or pSer129 α-syn
levels was observed between 3-month-old G2019S KI
mice and WT controls (Fig. 8c, d).
Discussion
We previously reported that G2019S KI mice have a
hyperkinetic phenotype relying on elevated kinase activ-
ity [43]. In this follow-up, we show that 12-month-old
G2019S KI and WT mice bear similar numbers of nigral
DA neurons and striatal DA terminals, in keeping with
previous studies in the same genotype [29, 92] or in
Fig. 4 Acute blockade of LRRK2 kinase activity does not affect striatal dopamine (DA) levels whereas acute DAT blockade evoked blunted
neurochemical and behavioral responses in G2019S knock-in (KI) mice in vivo. Microdialysis was performed in the dorsolateral striatum of
19-month-old G2019S KI mice and with age-matched wild-type (WT) littermates (WT) (a, b). Mice were then challenged with the LRRK2 kinase
inhibitor Nov-LRRK2-11 (10 mg/kg, i.p.) or the DAT blocker GBR-12783 (20 mg/kg, i.p.). Dialysate levels of DA are expressed as absolute values
(nM) and are mean ± SEM of 5 WT and 6 G2019S KI mice (a), or 6 WT and 9 G2019S KI mice (b). Motor responses of 12-month-old mice to
GBR-12783 (6 mg/kg, i.p.) or saline administration (c-e). Motor activity was assessed using the bar (c), drag (d) and rotarod (e) tests, before (baseline)
and after (20 and 90 min) drug administration, and was expressed as percentage of performance at baseline. Data are means ± SEM of 12–17 (WT) or
13–17 (G2019S KI) mice per group. Statistical analysis was performed using one-way RM ANOVA (a-b) or conventional ANOVA (c-e) followed by the
Newman–Keuls test for multiple comparisons. *p < 0.05, ** p < 0.01 significantly different from baseline values; #p < 0.05, ##p < 0.01 significantly
different from saline
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BAC G2019S overexpressing mice [40, 53] and rats [37,
74, 93], as well as similar extracellular DA levels and
depolarization-evoked striatal DA release, in line with
that found in 22-month old R1441G KI mice [82]. Since
the LRRK2 kinase inhibitor Nov-LRRK2-11 [43] also
failed to affect striatal DA release in vivo in any geno-
types, we conclude that the nigro-striatal DA system is
morphologically intact and the exocytotic properties of
DA neurons are functionally preserved in G2019S
LRRK2 carriers.
The lack of changes of striatal DA release is at strik-
ing variance with the 60% reduction in basal striatal
extracellular DA levels reported, in the absence of
motor phenotype change, in 12-month-old G2019S KI
mice [92]. We cannot easily explain this difference
since both strains of G2019S KI mice are backcrossed
on C57BL and bear similar kinase-enhancing mutations
on exon 41 [29, 92]. Indeed, kinase activity appears to
be elevated in both strains, as evaluated by in vitro kin-
ase assays on synthetic substrates [29, 92]. We con-
firmed this finding in vivo, showing that, in good
agreement with previous work on brain lysates of BAC
G2019S mice [72], pSer1292 levels were ~8-fold higher
in the striatum of G2019S KI mice compared to WT
controls. pSer1292 appears a more reliable marker of
kinase activity with respect to ATP γ-phosphate incorp-
oration measured in in vitro assays. Indeed, Ser1292
LRRK2 is an autophosphorylation site, and pSer1292
levels correlate with in vivo kinase activity [72].
pSer1292 levels are a more reliable readout of in vivo
LRRK2 kinase activity even compared to pSer935 levels,
since LRRK2 is phosphorylated at Ser935 by other ki-
nases [14, 20, 67]. The discrepancies between these two
strains of G2019S KI mice might be explained by quan-
titative differences in kinase activity along with inter-
individual genomic variability, motor tests used, or en-
vironmental conditions.
Despite the lack of changes of DA release, the levels
and functions of proteins involved in DA synaptic load
(DAT) and vesicular storage (VMAT2) were altered in
12-month-old G2019S KI mice. Strikingly, these changes
were age-dependent, since they were not observed in 3-
month-old animals, indicating these changes are ele-
ments of an orchestrated, progressive response relying
Fig. 5 Age-dependent dysfunction of DAT expression and function in G2019S knock-in (KI) mice. Kinetic analysis of [3H]-DA uptake in synaptosomes
(a, c), and Western blotting analysis of DAT protein levels (and representative blots) (b, d) were performed in the striata of 12-month-old (a, b) and
3-month-old (c, d) G2019S KI mice in comparison with age-matched WT controls. Values are expressed as mean ± SEM of n = 4 (uptake) or n = 3
(Western blotting) independent experiments performed in duplicate. Statistical analysis was performed using the Student t-test, two-tailed for unpaired
data. *p < 0.05, different from WT
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on the interaction between a genetic factor (the G2019S
mutation) and aging, i.e. the main risk factor in PD.
DAT was upregulated in G2019S KI mice, which
might represent a vulnerability factors for DA neurons
[56]. Indeed, DAT overexpression has been associated
with an increase of oxidative stress and neuronal degen-
eration [50] likely because cytosolic DA accumulation
causes the buildup of reactive oxygen species and qui-
nones, generated by DA autoxidation [25, 77, 79]. More-
over, cytosolic DA is metabolized by monoamine oxidase
A to DOPAL, which causes synaptic dysfunction and ter-
minal loss acting via different mechanisms, including
cross-linking with α-syn [9]. Finally, environmental
toxins causing PD, such as the toxic metabolite of
MPTP, MPP+, are taken up by DA neurons through
DAT. In fact, the greater susceptibility of BAC hG2019S
overexpressing mice to the parkinsonian toxin MPTP
can be explained by DAT upregulation [32].
Quite paradoxically, the increase of DAT activity was
associated with a blunted neurochemical and behavioral
response to GBR-12783. This is consistent with micro-
dialysis works reporting a 35–50% reduction of
nomifensine-induced DA release in the striatum of KI
mice constitutively expressing R1441G LRRK2 [39] or
temporally expressing G2019S LRRK2 [93]. Previous
studies in cells have shown that DAT expression levels
Fig. 6 Age-dependent dysfunction of VMAT2 expression and function in G2019S knock-in (KI) mice. Motor activity in 12-month-old G2019S KI
mice and wild-type (WT) littermates treated with reserpine (1 mg/kg, i.p.) or saline, and challenged in the bar (a), drag (b) and rotarod (c) tests,
before (baseline) and after (24 and 48 h) drug administration. Motor performance was expressed as percentage of performance at baseline. Data
are means ± SEM of n = 14–15 mice per group and were analyzed using conventional ANOVA followed by the Newman–Keuls test for multiple
comparisons. #p < 0.05, ##p < 0.01 significantly different from saline. Kinetic analysis of [3H]-DA uptake in whole-brain vesicles and Western blotting
of VMAT2 levels in the striata from 12-month-old (d-f) or 3-month old (g- i) G2019S KI mice and WT littermates. In Western blotting, two different
anti-VMAT2 antibodies were used, one commercially available (e, h; Sigma) and another developed by Miller lab (f, i) (see Methods). Data are
expressed as mean ± SEM of 4 mice (d- f), 3 mice (g) or 5 mice (h, i) per group, performed in duplicate. Statistical analysis was performed by the
Student t-test, two-tailed for unpaired data. **p < 0.01, different from WT
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inversely correlate with the potency of DAT blockers
[12], a phenomenon also observed for the serotonin
transporter [65]. Membrane DAT is in equilibrium be-
tween oligomeric and monomeric forms, and it has
been hypothesized that higher DAT expression leads to
higher DAT oligomerization, and DAT oligomers have
lower affinity for DAT blockers with respect to mono-
mers [38].
In line with that found in G2019S overexpressing mice
[41], G2019S KI mice showed reduced striatal VMAT2
levels. This reduction was robust and consistent with the
two different antibodies, one of which validated in
VMAT2+/- mice [15]. Reduction of VMAT2 is observed
also in PD patients [55] and is pathogenic in PD. In fact,
filling synaptic vesicles via VMAT2 is a way to keep
cytosolic DA levels in a nontoxic range; accordingly,
Fig. 7 DOPAL-modified α-synuclein (α-syn) levels are unchanged whereas Ser129-phosphorylated α-synuclein (pSer129 α-syn) levels are elevated
in G2019K knock-in (KI) mice. Relative quantification and representative blots of DOPAL-bound α-syn pull-down with aminophenylboronic acid
(APBA) resin of striata from 12-month-old G2019S KI mice and age-matched WT controls (a). In the same preparation, pSer129 α-syn levels (c)
were quantified relatively to α-syn levels (b). Data are expressed as mean ± SEM of n = 11 mice per group. Statistical analysis was performed by
the Student t-test, two tailed for unpaired data. **p < 0.01 different from WT
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VMAT2 deletion induces neurodegeneration [80]
whereas VMAT2 overexpression protects DA neurons
[10, 42]. However, despite VMAT2 reduction further en-
hanced the already higher DAT/VMAT2 ratio in nigro-
striatal DA neurons, thus increasing their vulnerability
[56], G2019S KI mice did not show overt neurodegener-
ation (up to 19-months at least) or even significantly en-
hanced levels of DOPAL-bound α-syn, a marker of DA
cytotoxicity. This questions the physiological meaning of
the 50% reduction of VMAT2 observed in the striatal
homogenate of G2019S KI mice. Indeed, contrary to that
expected from the Western blot data, an increase in
tetrabenazine-sensitive vesicular DA uptake was mea-
sured in G2019S KI mice in vitro. Although we cannot
rule out the possibility that such increase is compensa-
tory in nature, the possibility that this discrepancy relies
Fig. 8 Age-dependent overload of Serine129-phosphorylated α-synuclein (pSer129 α-syn) in G2019S knock-in (KI) mice. Representative micropho-
tographs and relative quantifications of α-syn and pSer129 α-syn immunostaining in the striatum of 12-month-old (a, b) and 3-month-old (c, d)
G2019S KI mice and WT controls. Data are expressed as mean ± SEM of 8 (a, b) or 6 (c, d) mice per group. Statistical analysis was performed by
the Student t-test, two tailed for unpaired data. *p < 0.05 different from WT
Longo et al. Acta Neuropathologica Communications  (2017) 5:22 Page 12 of 17
on technical reasons should be considered. In fact, the
reduction of VMAT2 levels measured in striatal hom-
ogenate might not faithfully reflect a reduction of active
VMAT2 expressed on mature, release-prone synaptic
vesicles. In fact, VMAT2 levels measured by Western
blot encompass also VMAT2 contained in immature
secretory vesicles trafficking from the soma to presynap-
tic vesicle membrane, or recycling from the plasma
membrane [30]. Interestingly, Sonsalla and collaborators
[30] proved a disparity between tetrabenazine binding
measured in striatal homogenate and striatal synaptic
vesicles at 24 h after MPTP, showing that, under certain
conditions, tetrabenazine binding measured in striatal
homogenate may not be representative of vesicular
VMAT2. On the other hand, the major limitation of a
whole-brain preparation of synaptic vesicles is hetero-
geneity. VMAT2 is present not only in striatal dopamin-
ergic terminals but also in noradrenergic, serotoninergic
and histaminergic terminals in striatal and extrastriatal
areas. Since there is no possibility to dissect out the con-
tribution of the different populations of VMAT2-positive
synaptic vesicles in this whole-brain preparation, we
cannot prove that the observed increase of vesicle up-
take is really due to VMAT2 expressed on striatal vesi-
cles, or is the net result of all changes of VMAT2
activity in different nerve terminals and brain areas.
Nonetheless, in favor of the hypothesis that vesicular
DA uptake might be increased rather than reduced in
G2019S KI mice, G2019S KI mice were relatively more
resistant than WT controls to the hypolocomotive action
of 1 mg/Kg reserpine in vivo, which is opposite from
that expected from DA depleted vesicles. We can specu-
late that the greater resistance to reserpine might be due
to a greater competition for VMAT2 of reserpine and
cytosolic DA (the increase in DAT activity and the
reduced DA turnover might overwhelm the buffering
capacity of VMAT2, thus causing an increase in cyto-
solic DA). Alternatively, we might speculate that synap-
tic vesicles in G2019S KI mice are more enriched in DA,
although only a trend to an increase in extracellular DA
levels or in the K+-induced DA release was observed in
the G2019S LRRK2 carriers.
It is therefore plausible that VMAT2 uptake elevation
compensates for the loss of VMAT2 protein and pro-
tects from cytosolic DA toxicity, even in the presence of
upregulated DAT. Whether this adaptive change will be
effective throughout the life-span of G2019S KI mice is
unknown, since we have investigated G2019S KI mice
up to 19 months. However, it is also possible that other
compensatory mechanisms will come into play to pre-
serve DA homeostasis and DA neuron integrity.
In this respect, one important finding of the present
study is that pSer129 α-syn levels are elevated in the
striatum of G2019S KI mice. Since this was not
paralleled by an elevation of total α-syn levels, we con-
cluded that G2019S LRRK2 facilitates this posttransla-
tional modification of α-syn. This is in line with a recent
study showing that the formation of pSer129 α-syn-
positive inclusions in nigral DA neurons in response to
intranigral α-syn fibrils injection is accelerated in BAC
hG2019S rats [86]. pSer129 α-syn [24] is the predomin-
ant form of syn in Lewy bodies [1], and for this reason it
has been hypothesized to favor α-syn aggregation, thus
contributing to PD [57]. However, the role of pSer129 α-
syn phosphorylation in α-syn toxicity in vivo is still
under debate [57, 81]. In fact, from the published litera-
ture it appears that depending on which kinase is
involved in Ser129 α-syn phosphorylation, either neuro-
toxicity (G protein receptor kinases) [11, 71] or neuro-
protection (Polo-like kinase 2) [58] can ensue. Moreover,
LRRK2, and more intensely G2019S LRRK2, can directly
Ser129-phosphorylate α-syn in vitro [63]. Pinning down
the pathway underlying Ser129 α-syn phosphorylation
might help understand whether this modification is pro-
tective or pathogenic for DA neurons.
Conclusion
We previously reported that G2019S KI mice have en-
hanced motor performance starting at 6 months of age
[43]. We now show that this behavior is not sustained
by enhanced DA release, suggesting that other mecha-
nisms, such amplified postsynaptic D1 receptor signal-
ling [54, 61] or glutamate release [3], might contribute.
Of note, this study reveals for the first time that
G2019S KI mice progressively develop (between 3 and
12 months) dysfunctions of plasma membrane and ves-
icular DA transporters, along with an overload of
pSer129 α-syn inclusions in striatum. These adaptive
changes were not associated with overt nigro-striatal
DA degeneration or changes of striatal DA release, in-
dicating DA homeostasis is preserved, at least up to 19-
months. Nonetheless, they might represent vulnerabil-
ity factors to DA neurons. A more stringent analysis of
the time-course of these changes might help elucidate
how this response of DA terminals is orchestrated, and
how these factors relate to each other and, ultimately,
to G2019S LRRK2. In fact, there is no evidence that
G2019S LRRK2 can directly affect DAT or VMAT2
trafficking, although this possibility is worth investigat-
ing due to the role of LRRK2 in endosome and autop-
hagosome pathways [68]. Nonetheless, G2019S LRRK2
could do so indirectly, through pSer129 α-syn. Indeed,
α-syn stimulates DAT activity [23, 36] and G2019S
LRRK2 has been shown to increase this property by
phosphorylating α-syn at Ser129 [27]. Preliminary evi-
dence that α-syn controls VMAT2 activity has also
been collected in cells where α-syn knockdown causes
an increase and A53T α-syn overexpression a reduction
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[22, 44]: nonetheless, the role of the pSer129 remains
unknown. Whatever the mechanistic interactions be-
tween these players are, the gradual development of
this response offers a wide time-window for a pharma-
cological intervention (e.g. with LRRK2 inhibitors) that
could establish the role of the kinase vs non kinase ac-
tivities of LRRK2.
In conclusion, G2019S KI mice might represent a pre-
symptomatic model of PD, a valuable tool to verify a
“multi-hit” hypothesis of PD [78], where genetic vari-
ables (G2019S LRRK2), an established risk factor (aging),
and internal (e.g. DA, α-syn) or environmental (e.g.
MPTP) factors interact to shape the emergence of the
parkinsonian phenotype.
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